2,4-bis(allyloxy)-1-ethylbenzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2,4-bis(allyloxy)-1-ethylbenzene
• 英文别名: 1-ethyl-2,4-bis-allyloxy-benzene；1-Aethyl-2,4-bis-allyloxy-benzol；2.4-Diallyloxy-1-aethyl-benzol；1-ethyl-2,4-bis(prop-2-enoxy)benzene
• 化学式: C₁₄H₁₈O₂
• 分子量: 218.296
• InChiKey: ATKVOUAHHSOROI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-乙基间苯二酚 、 3-溴丙烯 在 potassium carbonate 、 丙酮 作用下， 生成 2,4-bis(allyloxy)-1-ethylbenzene
  参考文献：
  名称：

  60.螯合研究。第三部分 邻羟基羰基化合物中的kekulé形式的稳定化

  摘要：

  DOI：

  10.1039/jr9360000274

文献信息

• Hsp90 family protein inhibitors
  申请人：Kitamura Yushi

  公开号：US20070155813A1

  公开（公告）日：2007-07-05

  wherein n is an integer of 0 to 10; R 1 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted heterocyclic-alkyl, substituted or unsubstituted aryl, —CONR 7 R 8 , —NR 9 R 10 , etc.; R 2 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, etc.; R 3 and R 5 may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, etc.; R 4 and R 6 may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, etc.) Provided are an Hsp90 family protein inhibitor comprising, as an active ingredient, a benzene derivative of formula (I) or a prodrug thereof or a pharmaceutically-acceptable salt thereof, etc.

  其中n为0到10的整数；R1代表取代或未取代的低碳基、取代或未取代的低碳氧基、取代或未取代的环烷基、取代或未取代的低碳氧羰基、取代或未取代的杂环烷基、取代或未取代的芳基、-CONR7R8、-NR9R10等；R2代表取代或未取代的芳基或取代或未取代的杂环基等；R3和R5可以相同也可以不同，分别代表氢原子、取代或未取代的低碳基等；R4和R6可以相同也可以不同，分别代表氢原子、卤素、取代或未取代的低碳基等。提供了一种Hsp90家族蛋白抑制剂，其包括以下化合物作为活性成分：公式（I）的苯衍生物或其前药或其药学上可接受的盐等。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• HSP90 FAMILY PROTEIN INHIBITOR
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1704856A1

  公开（公告）日：2006-09-27

  (wherein n is an integer of 0 to 10; R1 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted heterocyclic-alkyl, substituted or unsubstituted aryl, -CONR7R8, -NR9R10, etc.; R2 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, etc.; R3 and R5 may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, etc.; R4 and R6 may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, etc.) Provided are an Hsp90 family protein inhibitor comprising, as an active ingredient, a benzene derivative of formula (I) or a prodrug thereof or a pharmaceutically-acceptable salt thereof, etc.

  (其中 n 为 0 至 10 的整数；R1 代表取代或未取代的低级烷基、取代或未取代的低级烷氧基、取代或未取代的环烷基、取代或未取代的低级烷氧羰基、取代或未取代的杂环烷基、取代或未取代的芳基、-CONR7R8、-NR9R10 等；R2 代表取代或未取代的环烷基或取代或未取代的杂环基团等；R3 和 R5 可以相同或不同，各自代表氢原子、取代或未取代的杂环基团等。R2代表取代或未取代的芳基或取代或未取代的杂环基等；R3和R5可以相同或不同，各自代表氢原子、取代或未取代的低级烷基等；R4和R6可以相同或不同，各自代表氢原子、卤素、取代或未取代的低级烷基等）。 提供了一种 Hsp90 家族蛋白抑制剂，其活性成分包括式（I）苯衍生物或其原药或其药学上可接受的盐等。
• IDO INHIBITORS
  申请人：Newlink Genetics

  公开号：EP2227233A2

  公开（公告）日：2010-09-15
• US7538241B2
  申请人：——

  公开号：US7538241B2

  公开（公告）日：2009-05-26